Ombold

200 mennesker i udsatte positioner samles til idrætsdag i København18.9.2026 09:37:01 CEST | OmboldPresseinvitation

Tirsdag den 22. september samles 200 mennesker i udsatte positioner fra hele landet i Hafniahallen i Valby, når Idræt for Sindet, Ombold og Landsforeningen af Væresteder for første gang inviterer til Idræt & fællesskab. Deltagerne kan prøve alt fra fodbold, badminton og floorball til yoga, discgolf, dart og petanque. Thomas Bach, idrætschef i Københavns Kommune, åbner dagen. Medier inviteres med.
LEO Pharma

LEO Pharma announces FDA acceptance of dersimelagon NDA with Priority Review and closes acquisition from Tanabe Pharma18.9.2026 09:00:00 CEST | LEO PharmaPressemeddelelse

The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for dersimelagon for filing and granted it Priority Review, with a Prescription Drug User Fee Act (PDUFA) date expected by the end of February 2027. LEO Pharma has successfully closed the acquisition of dersimelagon from Tanabe Pharma, strengthening its late-stage pipeline and further leveraging its global dermatology platform. Dersimelagon is an investigational, once-daily oral melanocortin 1 receptor (MC1R) agonist for the treatment of erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), two rare genetic skin diseases with significant unmet medical need.
  • 1
  • 2
  • 3
  • 4
  • 5
  • Sidste
  • >>
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye